18th March 2025
Pri0r1ty Intelligence Group
PLC
("Pri0r1ty" or the
"Company")
Pri0r1ty Secures up to
£100,000 Contract with Leukaemia Care to Develop AI-Powered
Information Hub
Pri0r1ty Intelligence Group PLC (AIM:
PR1) is pleased to announce that it has secured a significant
contract with Leukaemia Care, one of the UK's leading blood cancer
charities (registered charity number 1183890). The agreement, worth
up to £100,000, will see Pri0r1ty AI Ltd, the company's wholly
owned subsidiary, develop and implement an AI-powered information
hub and website platform designed to enhance the charity's digital
capabilities and improve the charities overall communication with
donors and patients who are diagnosed and living with leukaemia and
those around them.
With over 10,000 people diagnosed
with Leukemia in the UK each year, this project will allow Pri0r1ty
and Leukaemia Care to deliver tangible support, particularly for
those seeking additional help for the first time. Delivering
enhanced access to Leukaemia Care's sector-leading information at
speed and scale for as many patients and potential supporters as
possible is a fundamental goal of the project. Under the terms of
the agreement, Pri0r1ty will deliver in two phases:
Phase 1 will focus on creating an
intuitive, user-focused information hub powered by Pri0r1ty's AI
technology, with a 24/7 AI assistant to guide users to relevant
information and support services. This phase will establish a
comprehensive digital platform that prioritises accessibility to
information, compliance with WCAG standards, and an enhanced user
experience across multiple devices. This initial phase will be
delivered for a fee of £50,000, part payable on signature of the
agreement with the balance to be settled upon agreed
milestones.
Phase 2 will commence upon
delivery of phase 1 and will expand the platform's capabilities to
include fundraising, and charity governance features, followed by
the integration of a custom CRM system to improve service delivery
and data-driven decision making. This phase will be delivered for
an additional fee of £50,000.
Leukaemia Care selected Pri0r1ty due
to the Company's expertise in AI-powered solutions and its desire
to deliver cost-effective digital transformation projects for
organisations of various sizes. The charity aims to leverage
Pri0r1ty's technology to establish an easier entry-point for the
organisations essential services, simplify navigation for users,
ensure key information is easily accessible, and enhance engagement
through personalised support delivered by AI.
This contract represents a
significant milestone for Pri0r1ty as it expands its presence in
the charity and healthcare sectors, demonstrating the versatility
of its AI platform across different industries. The project aligns
with the company's mission to deliver cutting-edge solutions that
streamline operations and enhance user experiences at an affordable
price point. Leukaemia Care will receive a year's subscription to
Pri0r1ty's core SaaS services included within their fee and
Pri0r1ty believe that this project will open up significant
opportunity for further AI consultancy projects to deliver strong
additional revenue to the group.
Colin Dyer, Chief Executive at Leukaemia Care,
said:
"We are looking forward to working
with the team at Pri0r1ty over the coming months and years to
develop easier and more impactful ways for patients, carers and
health professionals to access our services as we develop them to
meet what is an ever-increasing demand. We have been impressed with
the creativity and enthusiasm which the Pri0r1ty team have already
shown during the planning phase of this project."
James Sheehan, CEO of Pri0r1ty, commented:
"We are delighted to partner with
Leukaemia Care on this transformative technology project that we
believe will aid many people across the UK as well as within the
organisation. Our AI-powered solution will help the charity better
serve individuals affected by leukaemia by providing them with
personalised information and support through an intuitive digital
platform. This contract highlights the adaptability of our
technology and strengthens our position within the AI industry,
demonstrating we can deliver AI solutions that create tangible
value across different sectors.
"The charity sector faces unique
challenges in balancing resource constraints with the need to
deliver high-quality services. Our platform will enable Leukaemia
Care to enhance its digital capabilities without the need for
significant internal technical resources, allowing them to focus on
their core mission of supporting people living with
leukaemia."
If you would like to explore how
Pri0r1ty AI can help drive time and cost efficiency for your
business, please contact plc@pri0r1ty.com
For further information, please
contact:
Pri0r1ty Intelligence Group PLC
James Sheehan, Chief Executive
Officer
Email: ir@pri0r1ty.com
Nominated Adviser
Beaumont Cornish Limited
James Biddle/ Roland
Cornish
Email:
james@b-cornish.co.uk
Tel: +44 (0) 20 7628 3396
Broker
Allenby Capital Limited
Kelly Gardiner/ Jeremy Porter/ Piers
Shimwell
Tel: +44 (0) 20 3328 5656
Financial PR Adviser
Camarco
Marc Cohen, Gabriel Hedengren, Emily
Hall
Email:
Pri0r1ty@camarco.co.uk
Tel: +44 (0) 20 3757 4980
This announcement contains inside information for the
purposes of Article 7 of the Market Abuse Regulation (EU) No.
596/2014, as it forms part of UK Domestic Law by virtue
of the European Union (Withdrawal) Act 2018. Upon the
publication of this announcement, this inside information is now
considered to be in the public domain.
About Pri0r1ty Intelligence Group PLC
One of the few companies to list on
AIM last year, Pri0r1ty Intelligence Group is an AI company
providing professional growth services for SMEs. As an SME,
Pri0r1ty understands the unique challenges faced by small
businesses and has developed an AI Software-as-a-Service (SaaS)
platform tailored to their needs. Pri0r1ty's platform offers
cost-effective solutions that automate essential services like
social media management, investor relations, and corporate
governance. By reducing reliance on expensive external consultants,
Pri0r1ty empowers SMEs to streamline operations and focus on
growth.
About Leukaemia Care
Leukaemia Care is a national blood
cancer charity dedicated to ensuring that anyone affected by
leukaemia receives the right information, advice, and support. The
charity provides a range of services including a 24-hour helpline,
patient and carer support groups, and advocacy for better
treatments and care. Visit their website: https://www.leukaemiacare.org.uk/
Nominated Adviser Statement Beaumont Cornish Limited ("Beaumont Cornish"), is the
Company's Nominated Adviser and is authorised and regulated in the
United Kingdom by the Financial Conduct Authority. Beaumont
Cornish's responsibilities as the Company's Nominated Adviser,
including a responsibility to advise and guide the Company on its
responsibilities under the AIM Rules for Companies and AIM Rules
for Nominated Advisers, are owed solely to the London Stock
Exchange. Beaumont Cornish is not acting for and will not be
responsible to any other person for providing the protections
afforded to customers of Beaumont Cornish nor for advising them in
relation to the transaction and arrangements described in the
announcement or any matter referred to in it.
This information is provided by RNS,
the news service of the London Stock Exchange. RNS is approved by
the Financial Conduct Authority to act as a Primary Information
Provider in the United Kingdom. Terms and conditions relating to
the use and distribution of this information may apply. For further
information, please contact rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to
confirm compliance with the terms and conditions, to analyse how
you engage with the information contained in this communication,
and to share such analysis on an anonymised basis with others as
part of our commercial services. For further information about how
RNS and the London Stock Exchange use the personal data you provide
us, please see our Privacy Policy.
END
